NeoStem’s Stem Cell Therapy Fails Mid-Stage Heart Attack Study – TheStreet.com
Bidness ETC |
NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study
TheStreet.com Inject a cocktail of undifferentiated stem cells into a patient who has suffered a heart attack, and days or even weeks later, the stem cells transform into cardiac cells and rebuild the damaged heart muscle. Months later, the patient has a "new … Why NeoStem (NBS) Stock Might Decline Today NeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical … |
